Published in:
14-06-2022 | Prostate Cancer | Editorial
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
Authors:
Stefano Fanti, Jolanta Kunikowska, Jochen Walz, Wim Witjes, Anders Bjartell
Published in:
European Journal of Nuclear Medicine and Molecular Imaging
|
Issue 10/2022
Login to get access
Excerpt
A paper regarding consensus statements on the role of prostate-specific membrane antigen (PSMA) PET/CT (e.g. [
68Ga]Ga-PSMA-11, [
18F]PSMA-1007, [
18F]DCFPyL, herein and further referred to as “PSMA PET/CT”) in patients with prostate cancer and in respect to radioligand therapy ([
177Lu]Lu-PSMA) has recently been published in
Eur Urol Oncol [
1], resulting from a collaboration between European Association of Nuclear Medicine (EANM) and European Association of Urology (EAU). It is well known that PSMA PET/CT is increasingly used for men with prostate cancer (PCa) in various clinical settings, and now incorporated in several international guidelines [
2]; furthermore, procedural guidelines for performing PSMA PET/CT have been published [
3]. …